Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.
Company profile
Ticker
TNYA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
SEC CIK
Corporate docs
IRS number
813789973
TNYA stock data
Analyst ratings and price targets
Current price
Average target
$20.67
Low target
$13.00
High target
$28.00
Morgan Stanley
Maintains
$13.00
Chardan Capital
Maintains
$28.00
Canaccord Genuity
Initiated
$21.00
Latest filings (excl ownership)
8-K
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
7 Dec 22
8-K
Tenaya Therapeutics Announces Pricing of Public Offering
17 Nov 22
424B5
Prospectus supplement for primary offering
17 Nov 22
424B5
Prospectus supplement for primary offering
16 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
EFFECT
Notice of effectiveness
18 Aug 22
424B5
Prospectus supplement for primary offering
17 Aug 22
CORRESP
Correspondence with SEC
15 Aug 22
UPLOAD
Letter from SEC
12 Aug 22
Latest ownership filings
4
Change in insider ownership
23 Jan 23
4
DAVID V GOEDDEL
23 Jan 23
4
Change in insider ownership
19 Jan 23
4
DAVID V GOEDDEL
19 Jan 23
4
Deepak Srivastava
9 Dec 22
4
Amy L. Burroughs
7 Dec 22
3
Amy L. Burroughs
7 Dec 22
SC 13D/A
Casdin Capital, LLC
7 Dec 22
SC 13D
COLUMN GROUP III, LP
1 Dec 22
SC 13D/A
Casdin Capital, LLC
28 Nov 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.89 mm | 34.89 mm | 34.89 mm | 34.89 mm | 34.89 mm | |
Cash burn (monthly) | (no burn) | 6.89 mm | 10.43 mm | 9.77 mm | 2.40 mm | |
Cash used (since last report) | n/a | 26.88 mm | 40.67 mm | 38.09 mm | 9.34 mm | |
Cash remaining | n/a | 8.02 mm | -5.78 mm | -3.19 mm | 25.55 mm | |
Runway (months of cash) | n/a | 1.2 | -0.6 | -0.3 | 10.7 |
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 66 |
Opened positions | 21 |
Closed positions | 5 |
Increased positions | 20 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 275.68 mm |
Total shares | 43.02 mm |
Total puts | 24.10 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Column Group Iii | 9.40 mm | $178.14 mm |
Column | 9.40 mm | $27.26 mm |
Casdin Capital | 3.59 mm | $10.40 mm |
FMR | 3.13 mm | $9.06 mm |
RTW Investments | 2.46 mm | $7.13 mm |
BLK Blackrock | 2.44 mm | $7.08 mm |
T. Rowe Price | 2.11 mm | $6.13 mm |
Regents Of The University Of California | 1.63 mm | $4.72 mm |
Ra Capital Management | 1.60 mm | $4.65 mm |
T. Rowe Price Investment Management | 1.56 mm | $4.54 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Jan 23 | David V Goeddel | Common Stock | Buy | Acquire P | Yes | No | 2.4979 | 69,739 | 174.20 k | 9,870,274 |
19 Jan 23 | Column Group Iii GP | Common Stock | Buy | Acquire P | Yes | No | 2.4979 | 69,739 | 174.20 k | 9,870,274 |
18 Jan 23 | David V Goeddel | Common Stock | Buy | Acquire P | Yes | No | 2.5163 | 135,688 | 341.43 k | 9,800,535 |
18 Jan 23 | Column Group Iii GP | Common Stock | Buy | Acquire P | Yes | No | 2.5163 | 135,688 | 341.43 k | 9,800,535 |
17 Jan 23 | David V Goeddel | Common Stock | Buy | Acquire P | Yes | No | 2.4947 | 49,463 | 123.40 k | 9,664,847 |
17 Jan 23 | Column Group Iii GP | Common Stock | Buy | Acquire P | Yes | No | 2.4947 | 49,463 | 123.40 k | 9,664,847 |
News
Morgan Stanley Maintains Overweight on Tenaya Therapeutics, Lowers Price Target to $13
24 Jan 23
Tenaya Therapeutics, Clear Channel Outdoor And These 2 Penny Stocks Insiders Are Aggressively Buying
20 Jan 23
Tenaya Therapeutics Announces TN-201 IND Clearance And Anticipated 2023 Milestones
9 Jan 23
Tenaya Therapeutics Receives Orphan Drug Designation From FDA For Gene Therapy For Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
28 Nov 22
12 Health Care Stocks Moving In Friday's Pre-Market Session
25 Nov 22
Press releases
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
7 Dec 22
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
28 Nov 22
Thinking about buying stock in Canoo, Tenaya Therapeutics, Manchester United, Draganfly, or Meta Materials?
25 Nov 22
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
23 Nov 22
Tenaya Therapeutics Announces Closing of Public Offering
21 Nov 22